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Abstract Bloodstream infections due to Staphylococcus
aureus (BSI) are serious infections both in hospitals and in
the community, possibly leading to infective endocarditis
(IE). The use of glycopeptides has been recently challenged
by various forms of low-level resistance. This study
evaluated the distribution of MSSA and MRSA isolates
from BSI and IE in 4 Italian hospitals, their antibiotic
susceptibility—focusing on the emergence of hVISA—and
genotypic relationships. Our results demonstrate that the
epidemiology of MRSA is changing versus different STs
possessing features between community-acquired (CA)-
and hospital-acquired (HA)-MRSA groups; furthermore,
different MSSA isolated from BSI and IE were found, with
the same backgrounds of the Italian CA-MRSA. The
hVISA phenotype was very frequent (19.5%) and occurred
more frequently in isolates from IE and in both the MSSA
and MRSA strains. As expected, hVISA were detected in
MRSA with vancomycin minimum inhibitory concentra-
tions (MICs) of 1–2 mg/l, frequently associated with the
major SCCmec I and II nosocomial clones; this phenotype
was also detected in some MSSA strains. The few cases of
MR-hVISA infections evaluated in our study demonstrated
that 5 out of 9 patients (55%) receiving a glycopeptide,
died. Future studies are required to validate these findings
in terms of clinical impact.
Introduction
Staphylococcus aureus has become an increasing cause of
nosocomial and community acquired bloodstream infec-
tions (BSI), possibly leading to infective endocarditis (IE),
with a high risk of mortality despite aggressive therapy [1,
2]. Since 1990, the incidence of S.aureus bacteremia has
increased because of the extensive use of indwelling
intravenous catheters. Predisposing factors for S. aureus
infections include severe underlying conditions, prolonged
hospital stay, previous antibiotic treatment and nasal
carriage. In this context, the emergence of methicillin-
resistant S.aureus (MRSA) is a major clinical challenge,
particularly for the poor outcome related to such serious
infections, and for the increasing therapeutic failures. In
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challenged by various forms of reduced-susceptibility
(VISA and hVISA phenotypes), with consequential
effects on vancomycin efficacy in MRSA bacteremia
and endocarditis [3–5].
Until now, only a few studies have compared the
clinical and molecular features of MSSA versus MRSA
in patients with infective endocarditis or bacteremia [6–
12]. Additional knowledge could be useful to understand
and correlate the impact of specific genotypic markers
with clinical outcomes.
This study was undertaken to evaluate MSSA and
MRSA distribution in strains from BSI and IE isolated in
four Italian hospitals, in order to evaluate their genotypic
relationship, pvl gene distribution, antibiotic susceptibility
patterns and presence of hVISA strains.
Materials and methods
Microbial population and epidemiological correlations
The microbial population consisted of 128 S. aureus
clinical isolates, belonging to 76 patients with definite S.
aureus IE, according to the modified Duke criteria [13], and
52 patients with definite BSI. Patients were admitted to four
Italian hospitals (Modena, Bergamo, Perugia, and Rome)
between 2007 and 2009. The S. aureus isolates, randomly
selected (multiple isolates from the same patient and from
other patients at the same time in the same ward were
excluded) among all S. aureus isolates, were sent to our
laboratory for further characterizations. Infection classifica-
tion was performed as follows: nosocomial infection was
defined as an IE developing in a patient hospitalized for
>48 h before the onset of signs and symptoms consistent
with IE, and non-nosocomial health-care-associated infec-
tion was defined as an IE diagnosed within 48 h of
admission in an outpatient with extended health-care
contact. Persistent bacteremia was defined as >3 days of
bacteremia despite receipt of an antibiotic to which the
isolate was susceptible in vitro [14].
Microbiological characterization
Both groups of strains (BSI and IE) were all isolated
from blood cultures. All staphylococci were re-identified
at the species level by the catalase test, the S. aureus
agglutination test (Staphylase Test; Oxoid, Basingstoke,
Hampshire, UK) and biochemical tests (API-Staph sys-
tem; bioMérieux, Bagno a Ripoli, FI, Italy). Methicillin
resistance was evaluated by the cefoxitin disk diffusion
method and correlated with the presence of the mecAg e n e
[15–17].
Antimicrobial susceptibility was determined by the disk
diffusion method, according to CLSI guidelines [15]. All
isolates were tested against a panel of nine antimicrobial
agents as follows: ampicillin—1 μg, ciprofloxacin—5 μg,
chloramphenicol—30 μg, gentamicin—10 μg, erythromycin
—15 μg, clindamycin—2 μg, trimethoprim-sulfamethoxazole
—25 μg, rifampin—5 μg, and tetracycline—30 μg (Oxoid,
Milan, Italy).
In vitro susceptibility testing for vancomycin (Sigma
Chemical, St. Louis, MO, USA), teicoplanin, quinu-
pristin/dalfopristin (Aventis, West Malling, UK), line-
zolid (Pfizer, Groton, CT, USA), tigecycline (Wyeth
Pharmaceuticals, Collegeville, PA, UK) and daptomycin
(Novartis, Basel, Switzerland) was further performed
by the broth microdilution method to determine the
minimum inhibitory concentrations (MICs), following
the CLSI guidelines. The EUCAST guidelines were
also used for comparison [15, 16]. Heteroresistance to
glycopeptides was screened using the macro Etest
(bioMérieux), and confirmed by the reference PAP/AUC
method. S. aureus Mu3 (hVISA), Mu50 (VISA), and
A T C C2 9 2 1 3w e r eu s e da sc o n t r ol strains, as previously
described [18].
Molecular characterization of all strains was conducted by
PCR of mecAa n dpvl genes, SCCmec-typing, and MLST;
P F G Ew a sa l s ou s e do n l yt od e f i n ep o s s i b l er e l a t i o n s h i p s
among the isolates. All techniques were performed as
previously described [17]. MLST was performed on all
MRSA strains and on a selection of MSSA isolates (n =5 0 ) ,
based on phenotypic, genotypic, and susceptibility testing
differences (http://saureus.mlst.net/).
Clinical data on therapies for hVISA infections
All centers were asked to provide clinical data on the
treatment and outcome of patients with hVISA infections.
Overall, complete data were available for 20 out of 25
patients.
Results
Strain characteristics and infections
Overall, MSSA isolates were predominant, both in BSI and
IE, with only 32 out of 128 patients infected by MRSA
(Table 1). In particular, 41 out of 52 patients with bacteremia
were infected by MSSA (79%), while 11 by MRSA (21%);
55 out of 76 patientswithdefiniteS. aureus IE, were infected
by MSSA (72%), while 21 by MRSA (28%). Moreover,
community-acquired (CA)-MSSA strains represented the
leading cause of IE (60%), followed by hospital-acquired
(HA)-MRSA (25%), while MSSA were the main pathogens
740 Eur J Clin Microbiol Infect Dis (2012) 31:739–745responsible for BSI both in community-associated and in the
hospital isolates (Table 1).
All strains were epidemiologically and genetically
unrelated, as revealed by PFGE macro-restriction analyses
(data not shown).
Molecular analysis
As reported in Table 1, the molecular analysis performed by
MLSTshowed the spread of several hospital- and community-
associated clones, with different levels of diffusion, confirm-
ing, in part, the origin of the infections. A few exceptions
were found: in isolates from the IE-CA-MRSA group,
classical nosocomial isolates (ST228 SCCmec types I and
IA) were identified; on the contrary, in nosocomial IE-MRSA,
an increasing number of HA-MRSA strains carrying SCCmec
types IV (IVa, IVc, IVh) and V, which were traditionally
associated with community strains, were found (Table 2).
Generally speaking, ST5 and ST8 were uniformly repre-
sented both among MRSA and MSSA strains from both BSI
and IE. Two clones often associated with community-acquired
MRSA—ST30 and ST59—were particularly diffused only
among MSSA, while MRSA strains were frequently associated
with the major STs already described in nosocomial MRSA
strains. With regard to the SCCmec found, the SCCmec Ia n d
II were found associated predominantly with nosocomial STs,
while SCCmec IV and variants (IVc, IVh) and V were
associated with CA-MRSA clones. This behaviour is in
agreement with the major diffusion of CA-MSSA versus HA-
MRSA strains, both among IE and BSI S. aureus strains.
Among BSI-MRSA strains, hospital-associated isolates
represented the more frequent cause of infection (64%) and
were sustained by nosocomial clones, in which each
SCCmec-type was always associated with a specific genetic
background (suggesting clonal diffusion).
Molecular typing of CA-MRSA strains, belonging both to
BSI and IE, showed genetic backgrounds more frequently
associated with nosocomial clones (ST8-IV and ST228-I/IA
respectively), demonstrating the potential role of nosocomial
MRSA as a cause of serious infections in the community.
The pvl gene was found in four strains, and it was
preferentially associated with ST30 (n=2) and ST5 back-
grounds. A PVL-positive HA-MRSA strain belonging to
ST152 carrying a SCCmec V cassette (ST152-HA-MRSA-
V clone), was identified to be responsible for enhanced
severity of the disease (IE), correlating with multiple
therapeutic failures and mortality.
Antibiotic resistance
Concerning the antibiotic susceptibility profiles, a low rate
of resistance to non-beta-lactam drugs was observed among
MSSA, while MRSA strains showed the acquisition of
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Eur J Clin Microbiol Infect Dis (2012) 31:739–745 741resistance to fluoroquinolones (80%), erythromycin (42%),
gentamicin (35%), clindamycin (22%), rifampin (12%) and
tetracycline (10%). There were no significant differences in
antibiotic susceptibility patterns between the two groups,
i.e., BSI and IE.
With regard to the susceptibilities of the major anti-
Gram-positive drugs (Table 2), all S. aureus isolates
showed vancomycin and teicoplanin MIC90 values of
2 mg/l in both MRSA and MSSA: the only difference
between the two drugs was found in the IE-MSSA
subgroup in which teicoplanin showed a MIC90 value of
1 mg/l. Against all MSSA and MRSA strains, including
the hVISA ones, daptomycin (MIC90 0.5–1 mg/l), line-
zolid (MIC90 2–4 mg/l), quinupristin/dalfopristin (MIC90
0.5–1 mg/l), and tigecycline (MIC90 0.25–0.5 mg/l)
retained their full activity. A higher linezolid MIC90 value
was found in the MSSA and MRSA strains from BSI
(MIC90 4 mg/l) while the MIC90 of 2 mg/l was detected in
all other isolates. A reduced susceptibility to quinupristin/
dalfopristin (MIC 2 mg/l) was observed in 5 S.aureus
strains from IE (3 IE-MRSA and 2 IE-MSSA): overall, the
MIC90 values of this drug was maintained in the range of
susceptibility (MIC90 0.5–1m g / l ) .
hVISA behaviour
The screening with the Macro-Etest was applied to all
strains, and the positive ones were confirmed by PAP/AUC
analysis. In our laboratory, specificity and sensitivity values
for the Macro-Etest method, with respect to PAP/AUC,
were respectively 100% and 75% [18]. Table 2 shows their
distribution among the diverse groups and the correlation
with their genotypes. The hVISA phenotype was found
among all S.aureus strains, greater in IE (13.1% in MSSA
and 9.2% in MRSA) than in BSI (11.5% in MSSA and
3.8% in MRSA), but also greater in MS- than MRSA
isolates. It is relevant that this heteroresistant behaviour was
found in MSSA clones showing a MIC range of 0.5–1 mg/
l for vancomycin and 0.25–1 mg/l for teicoplanin. The
percentage of hVISA-MSSA strains was almost double
with respect to MRSA. In the MS-hVISA strains, despite
lower MIC values to vancomycin and teicoplanin, few
colonies were able to grow on agar plates containing 4–
6 mg/l of vancomycin, which is consistent with the hVISA
phenotype.
The molecular analysis of these strains revealed that
among all hVISA-MSSA isolates, two major genetic back-
grounds—ST8 (n=4) and ST30 (n=4), normally diffused in
the community independently from their origin, were
represented. Contrary to what was observed in MSSA
strains and, as expected, the hVISA-MRSA strains
belonged to the most prevalent nosocomial lineages
ST228-I (n=5), ST247-IA (n=2), and ST8-IA/IVc (n=2).
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Overall, complete data on therapy were available for 20 out
of 25 patients with an hVISA infection. The 11 patients
with an MS-hVISA infection were treated with oxacillin
with or without a glycopeptide, and all survived. On the
contrary, 5 out of 9 patients with an MR-hVISA infection
(55%) receiving a therapy with a glycopeptide died.
Discussion
In this study we investigated the molecular characteristics
and the resistance profiles of S. aureus isolated in persistent
bacteremia and in endocarditis during 2007–2009 in four
centers in Italy. Our sample comprised more MSSA than
MRSA strains isolated from both infections, approximately
half of them community-associated, in which CA-MSSA
strains were predominant. Patients’ records and settings
allowed us to distinguish CA-MRSA strains from nosoco-
mial strains, by epidemiological criteria: MLST analysis
and SCCmec-typing data demonstrated the changing epi-
demiology of MRSA in these infections, in which the
distinction between CA- and HA-MRSA is becoming
increasingly blurred. This is also confirmed by the high
proportions of mobile SCCmec type IV and V strains, as
well as a pvl-positive strain among HA-MRSA [19–21]. It
should be noted that the latter PVL-positive case, belonging
to ST152–SCCmec V, responsible for enhanced severity of
the disease (IE), correlated with multiple therapeutic
failures and patient mortality. The ST152–SCCmec V clone
had already been observed in Italy and in other countries,
always associated with severe infections [22–24].
With only the exception of the PVL-positive HA-MRSA
responsible for a severe form of IE, all other PVL-positive
strains were CA-MSSA belonging to ST5 and ST30,
exactly the same genetic backgrounds of the most diffuse
Italian PVL+ CA-MRSA clones [25, 26].
Strains of MRSA and MSSA from both BSI and IE
showed two common genetic backgrounds, ST5 and
ST8; two clones, often associated with community-
acquired MRSA–ST30 and ST59–were found only
among MSSA, showing that community genotypes have
already emerged in hospitals as a major cause both in
BSI and IE, independent of their association with
methicillin resistance [27].
Approximately one quarter of the isolates exhibited an
hVISA phenotype. In our data, this phenomenon was not
only present in MRSA strains, more frequent in IE than in
BSI, in which hVISA were found in well-described
nosocomial clones belonging to the agr type II [18] with
vancomycin MIC of 1–2 mg/l, but also in MSSA, in a
lower MIC range of 0.5–1 mg/l.
The study design did not include the association of the in
vitro results with clinical outcomes, and the few records
evaluated in the subset of hVISA infections, even if
indicating a possible glycopeptides failure trend, cannot
permit us to draw any definitive conclusion. The observa-
tion that 26% of S. aureus responsible for IE were hVISA at
least raises some concerns about the pressure that vanco-
mycin has exerted on these strains by prolonged sub-
therapeutic exposure. Furthermore, mortality data obtained
from all centers in 2007–2008 reported 10% mortality in
infections caused by MSSA, including those caused by
heteroresistant strains, and 28% in those by MRSA,
confirming the high risk of mortality if a methicillin-
resistant strain was found to be the main pathogen. It is well
documented that vancomycin shows a low level of
eradication due to its limited penetration into the valvular
vegetations [28].
With regard to reduced vancomycin susceptibility in
MSSA, only a few detailed reports exist in the
literature, some of them dealing with possible MRSA
precursors in which mecA had been lost. Pillai et al.
found hVISA in a series of clinical MSSA isolates from
patients who experienced vancomycin therapy failure, and
the authors concluded recommending attention in settings
in which MSSA infections are treated empirically with
vancomycin and in which these strains—owing to their
diffuse susceptibility—are not readily detected by routine
methods [29–32].
The MS-hVISA in our study belonged to different
clones, many of them found in the STs of the Italian CA-
MRSA. In particular, the MSSA genomes of strains
belonging to ST30 showed a high predisposition to be
heteroresistant and PVL-positive [33]. It is very difficult to
draw any conclusions on the emergence and role of these
strains with reduced susceptibility to vancomycin, but one
hypothesis could be the pressure exerted by widespread
glycopeptide use that is able to act simultaneously on
different, probably predisposed, bacterial clones.
Conclusion
In summary, this study makes several key observations. The
epidemiology of MRSA is changing and the distinction
between CA- and HA-MRSA is becoming increasingly
blurred in Italy, as is true elsewhere in the world.
Furthermore, in our strains, different MSSA isolated in
BSI and IE possessed the same backgrounds as the CA-
MRSA found in Italy.
The successful migration of clones from the community
seems to be a recent development. The SCCmec type IV
strain of MRSA may present some competitive advantages
over multidrug-resistant MRSA strains: it has been shown
to replicate more quickly and seems to affect patients who
Eur J Clin Microbiol Infect Dis (2012) 31:739–745 743are less ill [34]. On the other hand, most SCCmec type IV
MRSA clones are susceptible to many non-β lactam drugs,
providing an increasing number of therapeutic options
compared with the classic nosocomial strains.
The hVISA phenotype occurred more frequently in
isolates from IE and in both groups of strains. As expected,
hVISA was found in agrI and II HA-MR clones in a
vancomycin range of 1–2 mg/l [18], but our study also
highlights the presence of hVISA in MSSA with vancomy-
cin and teicoplanin susceptibility between 0.5 and 1 mg/l,
which demonstrated under-detecting and under-reporting
because it is hidden by a profile of full susceptibility. It is
necessary to emphasize that the 5 cases of glycopeptide
failure in MR-hVISA infections can only confirm the need
for studies evaluating the impact of hVISA in the clinical
outcome of severe infections.
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